Biological Correlation and Analysis
生物学关联与分析
基本信息
- 批准号:8325898
- 负责人:
- 金额:$ 32.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAntineoplastic AgentsApoptosisBiologicalBiological AssayCell Cycle ArrestCellsChemicalsCollaborationsComplex MixturesDoseEnzymesEvaluationFiberFoundationsHL60Hela CellsHistone DeacetylaseImmunodeficient MouseInduction of ApoptosisMolecularMolecular TargetMusNatural Product DrugPharmacologySolidSourceTestingTherapeutic IndexToxic effectWorkbasedrug discoveryin vivomulticatalytic endopeptidase complexoverexpressionprogramsresearch studytumor xenograft
项目摘要
_ , ...... =5 -;, .
Core A will focus on biological evaluation of extracts, chromatograpnic'fractions,'and pure isolates prepared
by all of the projects within the program in order to help prioritize subsequent biological and chemical work.
This strategy of using bioassay-guided isolation will afford us the opportunity to pursue biological activity
within complex mixtures. Extracts found active by Core A will be further purified by Projects 1-3 (OSU, UIC,
and RTI, respectively) and the pure isolates returned to us for further analysis. Promising pure compounds
will ultimately be further tested in animal models to assess efficacy and toxicity. Mechanism of action studies
will be conduced to study the molecular pharmacology of pure compounds with the most favorable
therapeutic indices. The Leader of Core A has well-established collaborations with all of the Project Leaders
of this Program Project and has previously employed a variety of assays for natural product drug discovery.
Our ongoing working relationships with other Projects and Cores and our ability to develop new biological
assays as needed will assure that Core A is fully integrated in the program project and serves all projects
therein. The Specific Aims for Core A are to (1) conduct molecular-target based assays including the histone
deacetylase assay (HDAC) and inhibition of the 20S proteasome. These assays will be conducted initially on
extract of materials Our second specific aim is to follow active leads identified by initial analysis using cell
based assays such as HL60, which is known to overexpress the 20S proteasome, or HeLa cells that are the
source of the HDAC used in the molecular target assays. Our third specific aim is to assess the activity of
our most promising active pure compounds in vivo. These experiments will include initial dose ranging
studies followed by efficacy studies using the hollow fiber assay or tumor xenografts studies in
immunodeficient mice. Finally, studies will be performed on those pure compounds that prove to be effective
anticancer agents with limited toxicity. in mice. These studies will focus on determining the mechanism of
action and may include studies such as pathway of apoptosis induction or mechanism of cell cycle arrest.
The biological assays outlined in this Core, used in concert with Cores B through D, will provide a solid
foundation of support for all the Projects within the program.
_, ......= 5 -; 。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN M SWANSON其他文献
STEVEN M SWANSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN M SWANSON', 18)}}的其他基金
Role of growth hormone in prostate cancer: rodent models
生长激素在前列腺癌中的作用:啮齿动物模型
- 批准号:
6479105 - 财政年份:2002
- 资助金额:
$ 32.63万 - 项目类别:
CHEMOPREVENTION OF BREAST CANCER BY OVARIAN HORMONES
通过卵巢激素化学预防乳腺癌
- 批准号:
2841577 - 财政年份:1996
- 资助金额:
$ 32.63万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 32.63万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 32.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 32.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 32.63万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 32.63万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 32.63万 - 项目类别:














{{item.name}}会员




